Use of a 'replication-restricted' herpes virus to treat experimental human malignant mesothelioma

Cancer Research

Volumn 57, Issue 3, 1997, Pages 466-471

  Kucharczuk, John C ^a   Randazzo, Bruce ^a,b   Chang, Michael Y ^a   Amin, Kunjlata M ^a   Elshami, Ashraf A ^a   Sterman, Daniel H ^a   Rizk, Nabil P ^a   Molnar Kimber, Katherine L ^a   Brown, S Moira ^c   MacLean, Alasdair R ^c   Litzky, Leslie A ^a   Fraser, Nigel W ^b   Albelda, Steven M ^a,b   Kaiser, Larry R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL RATE; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; GENE THERAPY; HUMANS; MESOTHELIOMA; MICE; MICE, SCID; MUTATION; SIMPLEXVIRUS; TUMOR CELLS, CULTURED; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0031052384     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Vile, R., and Russell, S. Gene transfer technologies for the gene therapy of cancer. Gene Therapy, 7:88-98, 1994.
2. Takamiya, Y., Short, M. P., Moolten, F. L., Fleet, C., Mineta, R., Breakefield, X. O., and Martuza, R. L. An experimental model of retrovirus gene therapy for malignant brain tumors. J. Neurosurg., 79:104-110, 1993.
3. Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (Washington DC), 256:1550-1552, 1992.
4. Boviatsis, E. J., Chase, M., Wei, M. X., Tamiya, T., R. K. Hurford, J., Kowall, N. W., Tepper, R. I., Breakefield, X. O., and Chiocca, E. A. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus (HSV), and retrovirus vectors. Hum. Gene Ther., 5:183-191, 1994.
5. Smythe, W. R., Hwang, H. C., Amin, K., Eck, S. L., Wilson, J. M., Kaiser, L. R., and Albelda, S. M. Successful treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex-thymidine kinase gene. Ann. Surg., 222:78-86, 1995.
6. Smythe, W. R., Hwang, H. C., Amin, K. M., Eck, S. J., Wilson, J. M., Kaiser, L. R., and Albelda, S. M. Recombinant adenovirus transfer of the HSV-thymidine kinase gene to thoracic neoplasms:an effective in vitro drug sensitization system. Cancer Res., 54: 2055-2059, 1994.
7. Freeman, S. M., Abboud, C. N., Wahrtenby, A., Packman, C. H., Koeplin, D. S., Moolten. F. L., and Abraham, G. N. The "bystander effect:" tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274-5283, 1993.
8. Russell, S. Replicating vectors for gene therapy of cancer: risks, limitations, and prospects. Eur. J. Cancer, 30: 1165-1171, 1994.
9. Dock, G. Influence of complicating diseases upon leukemia, Am. J. Med. Sci., 127: 536-592, 1904.
10. Asada, T. Treatment of human cancer with mumps virus. Cancer (Phila.), 34:1907-1928, 1974.
11. Smith, R. R., Huebner, R. J., Rowe, W. P., Schatten, W. E., and Thomas, L. B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer (Phila.), 9:1211-1218, 1956.
12. MacLean, A. R., UI-Farced, M., Robertson, L., Harland, J., and Brown, S. M. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the "a" sequence. J. Gen. Virol, 72:631-639, 1991.
13. Chou, J., Kern, E. R., Whilley, R. J., and Roizman, B. Mapping of herpes simplex virus neurovirulence to gamma 1 34.5, a gene nonessential for growth in culture. Science (Washington DC), 250:1262-1266, 1990.
14. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. I., and Coen, D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (Washington DC), 252:854-856, 1991.
15. Marken, J. M., Malick, A., Coen, D. M., and Martuza, R. L. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery (Baltimore), 32:597-603, 1993,
16. Randazzo, B. P., Kesari, S., Gesser, R. M., Alsop, D., Ford, J. C., Brown, S. M., MacLean, A. R., and Fraser, N. W. Treatment of experimental intracranial murine melanoma with a neuro-attenuated herpes simplex virus-1 mutant. Virology, 211:94-101, 1995.
17. Robertson, L. M., MacLean, A. R., and Brown, S. M. Peripheral replication and latency reactivation kinetics of the non-neurovirulent herpes simplex virus type-1 variant 1716. J. Gen. Virol., 73:967-970, 1992.
18. Spivack, J. G., Farced, M. U., Valyi-Nagy, T., Nash, T. C., O'Keefe, J. S., Gesser, R. M., McKie, E. A., MacLean, A. R., Fraser, N. W., and Brown, S. M. Replication, establishment of latent infection, expression of the latency-associated transcripts and expiant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye model. J. Gen. Virol., 76:321-332, 1995.
19. Valyi-Nagy, T., Fareed, M. U., O'Keefe, J. S., Gesser, R. M., MacLean, A. R., Brown, S. M., Spivack, J. G., and Fraser, N. W. The HSV-1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J. Gen. Virol., 75:2059-2063, 1994.
20. Kesari, S., Randazzo, B. P., Valyi-Nagy, T., Huang, Q. S., Brown, S. M., MacLean, A. R., Lee, V. M-Y., Trojanowski, J. Q., and Fraser, N. W. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest., 73:636-648, 1995.
21. Rusch, V. W. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest, 103: 382S-384S, 1993.
22. McKie, E. A., Hope, R. G., Brown, S. M., and MacLean, A. R. Characterization of the herpes simplex virus type 1 strain 17+ neurovirulence gene RL1 and its expression in a bacterial system. J. Gen. Virol., 75:733-741, 1994.
23. Smythe, W. R., Kaiser, L. R., Amin, K. M., Pitewski, J. M., Eck, S. L., Wilson, J. M., and Albelda, S. M. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann, Thorac. Surg., 57:1395-1401, 1994.
24. Juhasz, I., Albelda, S., Elder, D., Murphy, G., Adachi, K., Herlyn, D., Valyi-Nagy, I., and Herlyn, M. Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am. J. Pathol., 143:528-537, 1993.
25. Fung, K. M., and Trojanowski, J. Q. Animal models of meduloblastomas and related primitive neuroendocrine tumors. J. Neuropathol. Exp. Neurol, 54:285-296, 1995.
26. McKie, E. A., MacLean, A. R., Lewis, A. D., Cruickshank, G., Rampling, R., Bamett, S. C., Kennedy, P. G. E., and Brown, S. M. Selective In vitro replication of herpes simplex virus type l (HSV-1) ICP34.5 null mutants in primary human CNS tumors - evaluation of a potentially effective clinical therapy. Br. J. Cancer, 74:745-752, 1996.
27. Chou, J., and Roizman, B. The γ1 34.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc. Natl. Acad. Sci. USA, 89:3266-3270, 1992.
28. McGeoch, D. J., and Barnett, B. C, Neurovirulence factor. Nature (Lond.), 353:609, 1991.
29. Lord, K. A., Hoffman-Liebermann, B., and Liebermann, D. A. Sequence of MyD116 cDNA:a novel myeloid differentiation primary response gene induced by IL6. Nucleic Acids Res., 18: 2823-2828, 1990.
30. Chou, J., and Roizman, B. Herpes simplex virus 1 γ1 34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc. Natl. Acad. Sci. USA, 91:5247-5251, 1994.
31. Randazzo, B., Kucharczuk, J. C., Litzky, L., Kaiser, L., Brown, S., MacLean, A., Albelda, S., and Fraser, N. Herpes simplex 1716 - an ICP 34.5 mutant - is severely replication restricted in human skin xenografts in vivo. Virology, 223:392-396, 1996.